

MilliporeSigma Response to the COVID-19 Pandemic

At MilliporeSigma, we are helping to respond to the COVID-19 pandemic with products and solutions which empower scientists to detect and characterize viruses and to develop vaccines and therapies.

As a global life science tools and equipment supplier, we are committed to providing researchers with the necessary raw materials, products and services that can aid the global scientific effort to fight this novel virus. We have consolidated this product offering on a dedicated COVID-19 [Web page](#), providing a one-stop-shop of approximately 125 products and corresponding information for academic labs and biopharmaceutical companies working to combat the virus.

As a company committed to solving tough problems and accelerating access to health, we are not only focused on end-product solutions during this extraordinary time. To provide this level of support for the critical measures now underway to contain and treat COVID-19 and to continue providing products that support the development and manufacturing of over-the-counter drugs to complex cell and gene therapies, we are working hard to ensure minimal disruption to our supply chain while remaining committed to the safety of our employees and customers. Our 59 manufacturing sites around the world remain operational to ensure that our biopharmaceutical customers have the products and services they need to serve the health needs of a global population.

Along with this, our top priority remains the safety and well-being of our employees. At each of our sites, we have stopped travel, arranged remote working whenever possible and implemented stringent safety measures, such as social distancing and enhanced hygiene protocol. We are leveraging virtual meeting technology to continue collaborating with the global scientific community. Our leaders are working to keep our employees informed through a number of channels — from email to virtual town halls as well as a global network of hotlines — to answer employee questions in each country, address company policies, offer guidelines on working from home, and provide resources from the WHO, CDC, local governments and our benefits providers.

To aid the ongoing scientific response to COVID-19, we continue to monitor the global situation closely, establishing protocols and guidelines to minimize the impact whenever possible to our sites and supply. We have mobilized a global task force to actively evaluate the overall supply chain of both our products and key raw materials suppliers to mitigate any potential disruption. Leveraging business continuity plans, we remain dedicated to serving our customers in all markets. In China, our suppliers continue to increase their levels of resumed operations and, as shipping lanes in and out of China continue to improve, we are actively monitoring logistic routes and transportation options to fulfill our shipping requirements.

Throughout all of this, we are following guidance outlined by the WHO, CDC and governments of impacted countries, and our global sites have relevant and approved preparedness plans and are empowered to act per their local scenarios, as necessary.

For more information, contact:
Rachel Bloom-Baglin



External Communications
+1 978 436 1725
rachel.bloom-baglin@milliporesigma.com